Navigation Links
Abbott Introduces Molecular Diagnostic System Intended for Broad Identification of Infectious Agents
Date:7/21/2009

CHICAGO, July 21 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today unveiled its new PLEX-ID system currently in development for detecting and characterizing a wide range of pathogens, including infectious agents commonly transmitted in hospitals and other clinical sites. PLEX-ID is the next generation of Abbott's Ibis T5000(TM) Biosensor System and is among an innovative portfolio of instruments and tests the company is featuring this week at the American Association for Clinical Chemistry's 2009 Clinical Lab Expo.

"Research reported in several scientific venues has shown that the Ibis technology could offer applications for the rapid detection of a broad range of microbes, including bacteria, viruses and fungi, in a variety of specimens," said David Ecker, Ph.D., divisional vice president, research and development, Abbott Molecular.

Currently intended to be for research use only, PLEX-ID is a high-throughput technology that simultaneously enables identification and recognition of emerging organisms using a unique combination of both PCR (polymerase chain reaction) and mass spectrometry analysis for detection of microbes.

The system is designed to address a significant unmet clinical need by providing results in six to seven hours instead of three or more days as is required with culturing methods.

"The Ibis technology has demonstrated broad utility in a variety of research applications, including biodefense, forensics, epidemiology and infectious disease surveillance for public health applications," said Stafford O'Kelly, head of Abbott's molecular diagnostics business. "We believe the technology has the potential to be a powerful and versatile tool, particularly for the identification of hospital-borne pathogens."

The PLEX-ID is expected to receive CE Mark (Conformite Europeenne) for marketing in the European Union later this year.

Initial assays in development include bacteria-candida-antibiotic resistance (BCA), influenza and broad viral detection.

In an early research study, viral isolates from adenovirus, alphavirus, enterovirus, flavivirus, herpes virus and human parvovirus B19 were injected into human plasma specimens from healthy volunteers. This was followed by a retrospective study of 54 blinded samples of cerebral spinal fluid, urine and plasma. The Ibis technology detected all viral pathogens that were added to the plasma specimens with a limit of detection ranging from 15 to 125 copies. In the retrospective study, the system demonstrated 98 percent concordance with the reference method.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available at the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott Launches New Instrument to Complete Family of ARCHITECT Immunochemistry Analyzers
2. Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
3. Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal(R) Vet, a New Chemotherapeutic Agent for Dogs
4. Abbott Hosts Conference Call for Second-Quarter Earnings
5. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
6. Schmidt & Clark, LLP: FDA Reports Show Abbott Labs Subsidiary Failed to Disclose Parasite Eye Infections Tied to Contact Lens Solution
7. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
8. Abbott Declares 342nd Consecutive Quarterly Dividend
9. Abbott Announces Launch of Next-Generation Embolic Protection System
10. Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging
11. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... to expand access to affordable hearing aids , increase industry transparency, and ... in the United States. , “For the average consumer, the hearing aid industry ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... sealing company , is proud to announce that many of their franchises have ... customer service. The hard surface restoration franchises received customer recognition through positive reviews ...
(Date:2/8/2016)... ... 08, 2016 , ... The Federal Laboratory Consortium for Technology ... site houses a wealth of federal resources that businesses can leverage to further ... transfer (T2). As a network of over 300 federal laboratories, the FLC’s mission ...
(Date:2/8/2016)... ... ... who has struggled to quit smoking, a man who has struggled with hair loss – ... his problems – and he did. Now Nabat, a serial entrepreneur featured as the October ... to the world and better people's lives. His own experience with nicotine addiction led to ...
(Date:2/8/2016)... ... 2016 , ... The Bell Agency, a full service insurance ... their ongoing community enrichment program. The current campaign fundraises for Angels & Doves, ... being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded in ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... DUBLIN , Feb. 9, 2016  Jazz Pharmaceuticals ... will report its 2015 fourth quarter and full year ... close of the financial markets.  Company management will host ... 4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter ... business and financial update and guidance for 2016 financial ...
(Date:2/9/2016)... February 9, 2016 Amarantus BioScience ... on developing products for Regenerative Medicine, Neurology and Orphan ... presenting company at Source Capital Group,s 2016 Disruptive Growth ... 2016 in New York City . ... 10, 2016 at 12:30 pm by Gerald E. ...
(Date:2/9/2016)... , Feb. 9, 2016 The new report "Global Blood Monitoring ... Acuity Business Research & Consulting group reveals that global market for ... million in 2014 and expected to grow to US$ 24,830.1 million ... North America , Europe ... , Middle-East and Africa ...
Breaking Medicine Technology: